J&J ‘s
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn’s disease
Tremfya, United States Food and Drug Administration, Crohn ‘s disease, Approved, CD, J&J ‘s
Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation
This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.